Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
about
Adjuvant systemic therapy in older women with breast cancerFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewOptimal management of breast cancer in the elderly patient: current perspectivesSuivi après le traitement du cancer du sein: Guide pratique des soins aux survivantes à l’intention des médecins de familleFollow-up after treatment for breast cancer: Practical guide to survivorship care for family physiciansRacial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewOral antineoplastic agents: how do we care about adherence?Medication adherence in the general populationCYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive EarlyAdherence with capecitabine: A population-based analysis based on prescription refill data.Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Aromatase inhibitors-induced bone loss in early breast cancer.Adherence to hormone therapy among women with breast cancerFactors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Breast cancer, sickness absence, income and marital status. A study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosisInfluence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancerEarly discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsThe tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.Tamoxifen and CYP2D6: a contradiction of data.Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.Perspectives on adherence and persistence with oral medications for cancer treatment.Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyInfluence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study.Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trialUse of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.Patient adherence to aromatase inhibitor treatment in the adjuvant setting.Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.The Impact of Breast Care Nurses on Patients' Satisfaction, Understanding of the Disease, and Adherence to Adjuvant Endocrine TherapyHousehold net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysisThe effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients.Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
P2860
Q26741523-78A094E9-6C4B-4C2C-AA99-A8E0CEE4C6C1Q26850736-9FAFC6CE-6E59-4689-8583-65DB1FFAA268Q27690879-815B7607-8B9C-43F9-97E4-F87998591ED8Q28078524-A4CB318B-3322-4598-8891-C15FA5662883Q28080263-3BED6D22-1CC1-4848-85E1-15414E53ACE6Q28082674-10640EA1-7FBA-40F9-819A-D3E0541260B0Q28082909-83D2BA95-CDD7-437C-A5FC-1F83EAB528F6Q28484426-28821BD3-F6E0-4AD6-A684-82D9710C77E2Q30400967-FC411170-DD51-4120-8076-8F72B7F6135CQ30732631-46A02134-134B-482F-B88A-7D00B460F69DQ31140272-DA230533-DBD6-45AF-938E-450389BD6802Q33441090-1D6867AC-5DEB-4658-8C3D-70821673C2C7Q33752867-3BD779DB-D929-420A-B500-58ECB2965A74Q33755452-D4BA4ABD-6E72-488D-BE44-B6F493417E1CQ33756387-72C0E46E-BDDD-4150-A20D-7B96BE066AF0Q33857602-9F14C3EC-D2CF-4DCB-8C66-DADD5C10113AQ33867361-E336D983-C006-4055-93F7-7E2BAEA70257Q33874887-8507614D-9E46-43F2-9F4E-45847F4CAB37Q34174599-E4F061C0-EE85-481E-8F80-A6111B394ADFQ34193946-EB792954-CDE7-4B77-9FB0-7C620CF02AEBQ34205869-F6B05ACB-75EA-488B-A6B2-3DA174626C68Q34244463-963396D3-B021-4E82-953B-DB0CC1826706Q34355283-3A6B5D3B-0FC7-4383-9530-CF4ACC0319B8Q34445764-17446A33-A1F6-46C6-9786-42B7EFD95A8CQ34459748-E829F64C-72D0-45EC-938F-EB0CBAE0C4BDQ34529725-6E77295C-696C-4A6E-A93A-9D40C9A54BFCQ34736154-87703250-E424-496D-BD3A-14BBD78FF277Q34764981-076A19BE-C298-4694-9E5F-D04E619996C6Q34978630-C586028D-681A-44E5-907F-593CC776D5A0Q34991931-C4491BDB-0727-4AD3-8DB4-F47BB6B4AB28Q35006809-DEA947C6-BF70-438E-BF12-41E1E4CD0C69Q35059403-24B7AE77-B9D2-4887-866A-1FCC1F8B9C7AQ35075218-7CEBC1F1-9F2F-43B7-B150-B1B63762FCEFQ35095622-BE546447-6A1D-406A-B904-F6887E78BC16Q35168777-F59CEA4F-E23A-4FB7-82F0-CE17F31A5C89Q35573002-6D953DE3-7B46-4E58-BAEF-D77CC3475B6AQ35705287-97F876A3-7ADE-4279-BED7-F8F5B3D35642Q35742054-36E8E35A-F862-486D-8B38-5E069FA26723Q35903382-71460DAD-BB3F-40A1-9505-991E191B620FQ35938880-D5EDF6CC-C31D-4603-B75C-315B32D3D0BF
P2860
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@en
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@nl
type
label
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@en
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@nl
prefLabel
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@en
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
@en
P2093
U-S Albert
W Holzhauer
P2860
P304
P356
10.1093/ANNONC/MDN646
P577
2009-01-15T00:00:00Z